Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553550 | 0.84 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL17052668 | 0.83 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22703370 | 0.82 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL20370970 | 0.80 | MEN1 (0.36) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL21553509 | 0.78 | LPAR3 (0.42) | PPARD | |
| SCHEMBL13668048 | 0.77 | MEN1 (0.58) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL24275609 | 0.76 | MEN1 (0.37) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL27487331 | 0.75 | — | — | |
| SCHEMBL2288544 | 0.75 | TSHR (0.56) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22455497 | 0.74 | TSHR (0.74) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-07-02 | — | — | US | disclosed |
| US-10590416-B2 | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2019-12-19 | — | — | US | disclosed |
| EP-2895200-B1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | TRANSLATE BIO MA INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | MEN1 1361/4885KMT2A 3675/4885THRB 1556/4885 |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | MEN1 3131/4885KMT2A 3489/4885THRB 475/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | MEN1 1361/4885KMT2A 3675/4885THRB 1556/4885 |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | MEN1 1361/4885KMT2A 3675/4885THRB 1556/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | MEN1 1361/4885KMT2A 3675/4885THRB 1556/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MEN1 4753/4885KMT2A 1603/4885THRB 2042/4885 |
| US-10590416-B2 | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | SCNN1A, SCNN1G, SCNN1B | MEN1 1095/4885KMT2A 1278/4885THRB 1661/4885 |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | MEN1 2701/4885KMT2A 650/4885THRB 2661/4885 |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F12, F13A1, F13B | MEN1 1410/4885KMT2A 1240/4885THRB 3895/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MEN1 4828/4885KMT2A 3122/4885THRB 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.